Prostatis Group’s Confluent CFLT Stock Holding History

Prostatis Group’s Portfolio CFLT Stock Details CFLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,138	Closed	-$240K	–	167
2025 Q3	$240K	Buy	12,138 +2,044	+20%	+$42.8K	0.06%	152
2025 Q2	$252K	Buy	+10,094	New	+$228K	0.07%	133

Other funds holding CFLT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JCAM

Jericho Capital Asset Management New York $6.76B AUM 88.1% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ACM

Altimeter Capital Management Boston, Massachusetts $5.7B AUM 36.74% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Prostatis Group's CFLT Position: Q4 2025 in Review

Prostatis Group sold out of Confluent (CFLT) in Q4 2025, closing a stake of 12,138 shares — an estimated $240K sold.

Prostatis Group first reported a position in CFLT in Q2 2025 and held it in 2 quarters. The position peaked at $252K in Q2 2025. 426 funds tracked by Wall St. Rank hold CFLT as of Q4 2025.

Prostatis Group reported no remaining Confluent position as of Q4 2025 after selling out during the quarter.
Prostatis Group sold 12,138 Confluent shares in Q4 2025, an estimated $240K.
Prostatis Group first reported a position in Confluent in Q2 2025 and held it in 2 quarters.
Prostatis Group's Confluent position peaked at $252K in Q2 2025.
426 funds tracked by Wall St. Rank held Confluent as of Q4 2025.

Based on Prostatis Group's 13F filing for Q4 2025, filed 17 Feb 2026.